BioMarin Pharmaceutical Inc. $BMRN Stake Boosted by Secure Asset Management LLC

Secure Asset Management LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 11.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 78,208 shares of the biotechnology company’s stock after buying an additional 7,788 shares during the period. Secure Asset Management LLC’s holdings in BioMarin Pharmaceutical were worth $4,475,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of BioMarin Pharmaceutical in the second quarter worth approximately $39,000. CIBC Private Wealth Group LLC lifted its position in shares of BioMarin Pharmaceutical by 38.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 179 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter valued at approximately $40,000. Parallel Advisors LLC boosted its stake in BioMarin Pharmaceutical by 62.2% in the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 295 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new position in BioMarin Pharmaceutical in the 2nd quarter worth approximately $56,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Patent settlement adds potential royalty revenue: BioMarin reached a global agreement with Ascendis Pharma resolving patent disputes over Yuviwel. Ascendis will pay BioMarin royalties on Yuviwel sales in the U.S., European Union, Brazil and South Korea, removing a legal overhang and creating a potential recurring revenue stream. BioMarin Announces Global Settlement with Ascendis Pharma
• Positive Sentiment: Alesta acquisition expands the pipeline: BioMarin completed its acquisition of Dutch biotech Alesta Therapeutics. The deal adds ALE1, a potential first oral treatment for hypophosphatasia, giving investors another clinical catalyst and potentially broadening treatment options beyond BioMarin’s existing portfolio. BioMarin Announces Close of the Alesta Therapeutics Acquisition
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target from $88 to $90 and maintained an “overweight” rating. Jefferies also increased its target from $104 to $105 and kept a “buy” rating, indicating substantial potential upside based on analysts’ expectations. Analyst price target updates
• Neutral Sentiment: Rare-disease growth thesis remains intact: Zacks highlighted BMRN among rare-disease drugmakers with long-term growth potential, citing its products, pipeline catalysts and significant unmet medical needs. This supports the broader investment case but is not a new company-specific operating update. 4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
• Negative Sentiment: One analyst remains cautious: HC Wainwright raised its target modestly from $59 to $60 but retained a “neutral” rating, with the target below the recent trading level. This signals that some analysts view the stock’s valuation and near-term upside as limited. Analyst price target update

BioMarin Pharmaceutical Stock Down 0.6%

BioMarin Pharmaceutical stock opened at $64.84 on Wednesday. The firm has a market cap of $12.55 billion, a PE ratio of 175.24, a P/E/G ratio of 0.47 and a beta of 0.24. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm’s 50 day moving average price is $62.05 and its two-hundred day moving average price is $58.22. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same quarter last year, the business posted $1.44 EPS. The company’s revenue for the quarter was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, research analysts predict that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BMRN shares. Weiss Ratings cut shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group raised their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Barclays lifted their price target on BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Oppenheimer upped their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Finally, The Goldman Sachs Group assumed coverage on BioMarin Pharmaceutical in a research note on Monday, May 11th. They issued a “neutral” rating and a $69.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.00.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.